James B. Weissman - Jul 6, 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc (DRNA)

Role: Chief Operating Officer & EVP
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Stock symbol: DRNA
Transactions as of: Jul 6, 2021
Transactions value $: -$900,000
Form type: 4
Date filed: 7/8/2021, 08:17 PM
Next filing: Dec 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$273K	+30K	+187.5%	$9.09	46K	Jul 6, 2021	Direct
transaction	DRNA	Common Stock	Sale	-$1.17M	-30K	-65.22%	$39.09	16K	Jul 6, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-30K	-46.88%	$0.00	34K	Jul 6, 2021	Common Stock	30K	$9.09	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person sold an aggregate of 30,000 shares of Common Stock on July 6, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 3.78% of 794,128 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2020.
F3	The option vests in 48 monthly installments over the four-year period with a vesting start date of January 8, 2016, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.